Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report

Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management

(2013) Ayalew Tefferi   AMERICAN JOURNAL OF HEMATOLOGY

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

(2012) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

(2012) Claire Harrison et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis

(2011) P. Guglielmelli et al.   BLOOD

What are RBC-transfusion-dependence and -independence?

(2010) R.P. Gale et al.   LEUKEMIA RESEARCH

Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

(2010) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference

(2009) G. Barosi et al.   BLOOD

Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation

(2009) N. Kroger et al.   BLOOD

Thrombosis in primary myelofibrosis: incidence and risk factors

(2009) T. Barbui et al.   BLOOD

New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment

(2008) F. Cervantes et al.   BLOOD